title: Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.
abstract: Vascular safety is an emerging issue in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs). Whereas imatinib exhibits a well-documented and favorable long-term safety profile without obvious accumulation of vascular events, several types of vascular adverse events (VAEs) have been described in patients receiving second- or third-generation BCR/ABL1 TKIs. Such VAEs include pulmonary hypertension in patients treated with dasatinib, peripheral arterial occlusive disease and other arterial disorders in patients receiving nilotinib, and venous and arterial vascular occlusive events during ponatinib. Although each TKI interacts with a unique profile of molecular targets and has been associated with a unique pattern of adverse events, the mechanisms of drug-induced vasculopathy are not well understood. Here, recent data and concepts around VAEs in TKI-treated patients with CML are discussed, with special reference to potential mechanisms, event management, and strategies aimed at avoiding occurrence of such events in long-term treated patients.
authors.affiliation: Department of Internal Medicine I, Division of Hematology & Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria;
authors.forename: Peter
authors.identifier: http://orcid.org/0000-0003-0456-5095
authors.initials: P
authors.lastname: Valent
authors.affiliation: Department of Internal Medicine I, Division of Hematology & Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria; Department/Clinic for Companion Animals and Horses, Clinic for Small Animals, Clinical Unit of Internal Medicine, University of Veterinary Medicine Vienna, Vienna, Austria;
authors.forename: Emir
authors.identifier: http://orcid.org/0000-0001-7409-4204
authors.initials: E
authors.lastname: Hadzijusufovic
authors.affiliation: Department of Internal Medicine II, Division of Angiology, Medical University of Vienna, Vienna, Austria;
authors.forename: Gerit-Holger
authors.initials: GH
authors.lastname: Schernthaner
authors.affiliation: Medical Clinic III for Oncology, Haematology and Rheumatology, University Hospital Bonn (UKB), Bonn, Germany;
authors.forename: Dominik
authors.initials: D
authors.lastname: Wolf
authors.affiliation: Service d'Hématologie Adulte, Hôpital Saint-Louis, Paris, France; and.
authors.forename: Delphine
authors.initials: D
authors.lastname: Rea
authors.affiliation: Medical Clinic for Hematology and Oncology, Campus Virchow, Charité, Medical University of Berlin, Berlin, Germany.
authors.forename: Philipp
authors.initials: P
authors.lastname: le Coutre
mesh_terms: D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D014652:Vascular Diseases / Q000139:chemically induced* / Q000150:complications
chemical_list: D047428:Protein Kinase Inhibitors; D016044:Fusion Proteins, bcr-abl